Table 3.
A summary of clinical transformation of nucleic acid drugs based on EVs for cancer therapy.
| Country | Institution | Research Content | Payload | Clinical Trial Number |
|---|---|---|---|---|
| United States | Codiak BioSciences | exoASOTM-STAT6 | ASO | NCT05375604 (Phase I) |
| United States | M.D. Anderson Cancer Center | iExosomes | KRASG12D siRNA | NCT03608631 (Phase I) |
| United States | Vesigen Therapeutics | ARMMs technology | RNA/Gene editing | / |
| United States | Carmine Therapeutics | REGENT® platform | RNA/Gene editing | / |
| England | EVOX Therapeutics | DeliverEXTM platform | mRNA/Gene editing | / |
| China | Echo Biotech | Echosome® platform | / | / |
| China | VesiCURE | modEXOTM | / | / |
| Korea | EXOSOME plus | ExoTheraTM | / | / |
| Switzerland | Anjarium Biosciences | Hybridosome® delivery technology | DNA | / |